Active immunization against LHRH alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma.
Am J Reprod Immunol
; 34(3): 200-6, 1995 Sep.
Article
em En
| MEDLINE
| ID: mdl-8561879
ABSTRACT
PROBLEM:
To determine whether active immunization against LHRH can serve as treatment for androgen-dependent prostatic carcinoma.METHOD:
Male rats of Copenhagen X Fisher strain, implanted with Dunning R-3327 prostatic carcinoma cells were either immunized against LHRH, treated with LHRH-antagonist, or received a combined treatment of active immunization against LHRH and LHRH-antagonist.RESULTS:
Testicular histology was consistent with infertility in all treatment groups. The rate of tumor growth was inhibited by all three treatment regimens. Tumor size increased by 3.8 +/- 1.4 cm2 in the LHRH-antagonist group, 3.2 +/- 1.1 cm2 in the immunized group, and 1.0 +/- 0.4 cm2 in the combined treatment group, as compared to 8.2 +/- 2.6 cm2 in non-treated control group.CONCLUSION:
LHRH-antagonist administration combined with immunization against LHRH appeared to exert a synergistic effect. This may be due to the blockade of prostatic LHRH-like receptors by the antagonist, while androgen depletion was rapidly achieved by LHRH-antagonist, and maintained by continued gonadotropin suppression caused by active immunization against LHRH once antagonist treatment had been discontinued.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Carcinoma
/
Hormônio Liberador de Gonadotropina
/
Imunoterapia
/
Androgênios
Limite:
Animals
Idioma:
En
Revista:
Am J Reprod Immunol
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Estados Unidos